Oenon Holdings Inc

Oenon Holdings Inc has a market price of 490 JPY per share, with a market capitalization of 27.6 billion JPY. The company's price-to-earnings ratio is 8.9, and its price-to-book ratio is 1.05, indicating a valuation in line with tangible book value. The enterprise value to EBITDA ratio is 8.14, and the enterprise value to revenue ratio is 0.37, suggesting a relatively low valuation compared to revenue. The company's profitability is reflected in a return on equity of 11.85% and a return on assets of 5.24%. These figures are compared against the industry's preferred metrics, which emphasize high ROE and ROIC. Oenon's ROE is above the typical industry median, but its ROA is slightly below the median for Distillers & Wineries, indicating that asset utilization could be improved. Oenon's revenue is distributed across three segments: Alcoholic Beverage Business, Enzyme Pharmaceutical Business, and Real Estate Business. The Alcoholic Beverage segment is the largest contributor, with a significant portion of revenue derived from domestic sales in Japan. The company's geographic exposure is heavily concentrated in Japan, with limited international operations. The company's growth trajectory is modest, with a current fiscal year outlook showing a slight increase in revenue. The next fiscal year is expected to see a continuation of this trend, with a projected revenue growth of less than 5%. This is in line with the broader industry's conservative growth expectations. The risk assessment for Oenon Holdings Inc indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. However, the dilution risk is low, as the company has not issued new shares recently, and there is no indication of a near-term need for additional capital. Recent events include the filing of the 2023 annual report, which provides detailed financial and operational data. The report highlights the company's focus on maintaining profitability in the alcoholic beverage segment and expanding its enzyme pharmaceutical business. No significant regulatory or legal issues were disclosed in the latest filings.